Pharmaceutical Executive, Jun 1, 2010 - Pharmaceutical Executive

ADVERTISEMENT

Pharmaceutical Executive, Jun 1, 2010
Washington Report
Crackdown on Counterfeits
By Jill Wechsler
FDA and industry seek to ensure drug quality in a world complicated by global outsourcing and theft.
Columns
Boldly Going Where Many Have Gone Before
By Scott Connor, Acurian
Social networking helps sponsors drive clinical trials recruitment.
Managing Business Synergies
By Peter von Dyck, e-Zassi.com
Pharma companies can maximize partnership benefits with social media.
Moving Beyond Claims-Based Messaging
By Mike Mabey, CMI
Improving communication means appealing to physicians' heads as well as their hearts.
Back Page
Pew's Rising Profile in Public Health
By William Looney
The public-interest charity takes on pharma-influenced medicing and drug-resistant bacteria.
From the Editor
Post-Approval Regulation: Progress or Pileup?
By William Looney
Innovation in industry has always required a strong internal champion; the danger is a process led by the risk-adverse and externally-driven stakeholder consensus called "death by faint praise." Is this really what we mean by "bold partnerships?"
Features
Crackdown on the C-Suite
By Walter Armstrong
Lewis Morris, top lawyer in HHS's office of inspector general, explains his new move to target pharma execs for serious and ongoing healthcare fraud.
Riding the Wave
By Suri Harris, CAHG
A new "upstream" healthcare model may help deliver on the longstanding promise of personalized medicine.
Emerging Pharma Leaders 2010
By The Pharm Exec staff
Strong, skilled management is on the agenda as never before. Find out who made 2010's roster of high-potential change masters—and how they plan to lead the industry through the turbulent times ahead.

ADVERTISEMENT

Click here